Literature DB >> 10588848

Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome.

M G Torrioli, S Vernacotola, P Mariotti, E Bianchi, M Calvani, A De Gaetano, P Chiurazzi, G Neri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10588848

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN： 0148-7299


× No keyword cloud information.
  11 in total

Review 1.  Fragile X-associated disorders: a clinical overview.

Authors:  Anne Gallagher; Brian Hallahan
Journal:  J Neurol       Date:  2011-07-12       Impact factor: 4.849

Review 2.  Public Health Literature Review of Fragile X Syndrome.

Authors:  Melissa Raspa; Anne C Wheeler; Catharine Riley
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

Review 3.  Pharmacotherapy for Fragile X Syndrome: Progress to Date.

Authors:  Matthew H Davenport; Tori L Schaefer; Katherine J Friedmann; Sarah E Fitzpatrick; Craig A Erickson
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 4.  Treatments for fragile X syndrome: a closer look at the data.

Authors:  Scott S Hall
Journal:  Dev Disabil Res Rev       Date:  2009

Review 5.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.

Authors:  Claudia Bagni; Flora Tassone; Giovanni Neri; Randi Hagerman
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

7.  Acetyl-L-carnitine reduces impulsive behaviour in adolescent rats.

Authors:  Walter Adriani; Monica Rea; Marta Baviera; William Invernizzi; Mirjana Carli; Orlando Ghirardi; Antonio Caprioli; Giovanni Laviola
Journal:  Psychopharmacology (Berl)       Date:  2004-05-08       Impact factor: 4.530

Review 8.  Advances in the treatment of fragile X syndrome.

Authors:  Randi J Hagerman; Elizabeth Berry-Kravis; Walter E Kaufmann; Michele Y Ono; Nicole Tartaglia; Ave Lachiewicz; Rebecca Kronk; Carol Delahunty; David Hessl; Jeannie Visootsak; Jonathan Picker; Louise Gane; Michael Tranfaglia
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

9.  A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial.

Authors:  Yolanda de Diego-Otero; Rocio Calvo-Medina; Carolina Quintero-Navarro; Lourdes Sánchez-Salido; Francisco García-Guirado; Ignacio del Arco-Herrera; Isabel Fernández-Carvajal; Teresa Ferrando-Lucas; Rafaela Caballero-Andaluz; Lucia Pérez-Costillas
Journal:  Trials       Date:  2014-09-03       Impact factor: 2.279

Review 10.  Systematic review of pharmacological treatments in fragile X syndrome.

Authors:  Jose-Ramon Rueda; Javier Ballesteros; Maria-Isabel Tejada
Journal:  BMC Neurol       Date:  2009-10-13       Impact factor: 2.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.